Corti expands its clinical-AI platform to startups as Europe’s regulatory legislation increases.

      The company based in Copenhagen reports that its Symphony model has surpassed OpenAI on HealthBench Professional and is providing credits and regulatory assistance to entrepreneurs developing healthcare AI globally.

      Corti, the clinical AI company from Copenhagen, has introduced a no-equity accelerator aimed at startups in healthcare and life sciences, making its Symphony model stack available to founders around the world at a time when the costs of regulatory compliance for medical AI in Europe have reached unprecedented levels.

      On Tuesday, the company announced that its flagship clinical-grade model, Symphony, had outperformed OpenAI on HealthBench Professional, which is a benchmark for realistic clinician interactions released by OpenAI last month along with its ChatGPT for Clinicians offering.

      The new Startup Acceleration Program provides up to $5,000 in credits for the complete Symphony stack, which includes agents, medical coding, speech-to-text, and text generation technologies. According to the company, this stack has been trained on over 1.5 million hours of clinical audio.

      Participants will also gain direct access to Corti’s clinical and regulatory team regarding the EU AI Act, MDR, and data-residency inquiries, along with founder-led webinars on their roadmap and invitations to Corti events in New York, Copenhagen, London, and Berlin.

      Applications are currently being accepted on a rolling basis with a response time of one week. There is no pitching process or equity requirement, and the program is available to pre-seed through Series B companies in healthcare, clinical workflows, or related life sciences.

      This launch occurs amid increasingly stringent regulatory conditions. In April, OpenAI made free clinical AI available to all verified American healthcare professionals, including physicians, nurse practitioners, physician assistants, and pharmacists.

      However, a week later, OpenEvidence, the clinical AI search platform valued at $12 billion and utilized by approximately 40% of US doctors, withdrew from the UK and EU markets, citing regulatory ambiguities introduced by the EU AI Act.

      The obligations associated with high-risk systems from that decision will take effect on August 2, 2026, although AI embedded in CE-marked medical devices regulated under MDR or IVDR is subject to a separate timeline outlined in Article 6(1), currently set for August 2, 2027.

      Corti argues that the high structural costs in Europe present challenges for founders. The EU MDR certification process alone can cost between €200,000 and €600,000 per device and requires 12 to 18 months to complete, as indicated by industry guidance.

      Galen Growth’s analysis for Q1 2026 shows European digital health funding concentrating in larger, later-stage rounds, with investors increasingly preferring companies that can demonstrate clinical evidence and integration into workflows rather than just impressive performance figures.

      Andreas Cleve, Corti’s co-founder and CEO, stated, “The future of healthcare AI will not be created by a single entity, but by numerous teams possessing in-depth knowledge of specific care settings, workflows, or patient populations.”

      "Our mission is to provide these builders with a competitive advantage: the leading clinical AI model, the supporting evidence, and a path to production that we have already navigated for regulated health systems. This allows them to concentrate on what they do best—the workflows, the patient populations, and the problems they truly understand.”

      One of the teams currently utilizing Corti is Aisel Health, a European startup concentrating on psychiatric workflows.

      “Psychiatrists are a limited and highly specialized resource,” noted Augusta Klingsten Peytz, Aisel’s co-founder and CEO. “They should solely focus on clinical decision-making—everything else should be eliminated. Yet today, most of a psychiatrist’s time is spent on administrative tasks and repetitive workflows instead of making clinical decisions.”

      “By leveraging Corti, we at Aisel can concentrate on creating specialized psychiatric workflows that help clinicians regain their time rather than having to reconstruct the clinical-grade framework beneath.”

      Corti has successfully raised $100 million so far, with locations in Copenhagen, New York, and London. Its Symphony for Medical Coding release in April claimed a 25% accuracy advantage over OpenAI and Anthropic on ACI-BENCH and MDACE, two academic medical coding benchmarks. The company states that its stack powers AI for systems serving over 100 million patients annually, including the NHS.

      Corti frames the program’s premise as positing that the challenges faced by horizontal model providers in Europe are actually the conditions for which vertical clinical-AI players are best suited. Applications are open starting today.